Showing results (161-170 of 217) with videos related to
Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancerValentina Guarneri, Daniele Giulio Generali, Antonio Frassoldati, et al.The Oncologist|November 15, 2017
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast CancerMaria Vittoria Dieci, Valentina Guarneri, Tommaso Giarratano, et al.Translational Lung Cancer Research|February 11, 2021
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcomeAlberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, et al.Breast Cancer Research and Treatment|August 10, 2007
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancerValentina Guarneri, Antonio Frassoldati, Guido Ficarra, et al.Theranostics|February 28, 2019
MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic AdenocarcinomaFilippo Rossignoli, Carlotta Spano, Giulia Grisendi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB studyValentina Guarneri, Antonio Frassoldati, Alberto Bottini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2023
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialPierFranco Conte, Giancarlo Bisagni, Federico Piacentini, et al.Cytokine & Growth Factor Reviews|February 21, 2021
Anticancer innovative therapy congress: Highlights from the 10th anniversary editionFrancesca De Santis, Giovanni Fucà, Dirk Schadendorf, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast CancerPatrick Neven, Stephen R D Johnston, Masakazu Toi, et al.Clinical Lung Cancer|October 12, 2019
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid BiopsyAlessandro Dal Maso, Martina Lorenzi, Elisa Roca, et al.Pageof 22